Group 1 - The first domestically produced nine-valent HPV vaccine "Xinkening®9" has been approved for market release, priced at 499 yuan per dose, approximately 40% of the price of imported nine-valent HPV vaccines [2] - The vaccine was developed by a team led by Academician Xia Ning Shao from Xiamen University in collaboration with Wantai Biological Pharmacy, utilizing a novel prokaryotic expression system [2][3] - The development process took 18 years, involving over 20 PhD and 150 master's degree holders from Wantai Biological, marking a significant breakthrough in China's biopharmaceutical sector [2][3] Group 2 - Clinical trial results published in The Lancet Infectious Diseases indicate that "Xinkening®9" shows similar immune response and safety profiles compared to imported vaccines [3] - The vaccine effectively prevents persistent infections from seven high-risk HPV types associated with cervical cancer, establishing a protective barrier for women aged 18-45 [3] - The World Health Organization has initiated a global strategy to accelerate the elimination of cervical cancer, with China also launching an action plan that includes promoting HPV vaccination as a key objective [3] Group 3 - Wantai Biological has invested approximately 1 billion yuan in the research and development of the nine-valent HPV vaccine, with the approval of its market license expected to enhance the company's product line and core competitiveness [4] - The introduction of the domestically produced vaccine is anticipated to increase vaccination rates among eligible women, contributing to the establishment of a national immunity barrier against cervical cancer [4][5] - The affordable pricing of the vaccine is expected to benefit over 100 million women in China and positively impact global efforts to combat cervical cancer [5]